Immunotherapy and prevention of breast cancer

Muthanna Medical Journal
Volume 7, Issue 2,  2020 Page 58-70
http://dx.doi.org/10.18081/2410-4590/2020-58-70
Neelam Thacker 1, Perianayagam Taneja
* Correspondence author: Thackern@tmckolkata.com
1Tata Medical Center, Kolkata, India
Received 19 September 2020, Accepted 11 November 2020, Available online 16 December 2020

Abstract

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Keywords: Immunotherapy; prevention vaccines; breast cancer